12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

A-623: Phase IIb ongoing

Anthera disclosed in its 2Q11 earnings that a DSMB recommended continuation of the double-blind, international Phase IIb PEARL-SC trial based on a review of safety data from patients. PEARL-SC is comparing a weekly low or high dose of subcutaneous A-623, a monthly high...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >